
Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.
At AMCP 2019, C.E. (Gene) Reeder, RPh, PhD, director of outcomes research at the University of South Carolina, sheds light on the specialty drug category and the state of pharma rebate contracting.







